Advent Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Advent Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,000	Closed	-$3.38M	–	232
2025 Q3	$3.38M	Buy	+75,000	New	+$3.5M	0.07%	148
2023 Q3	–	Sell	-20,000	Closed	-$1.28M	–	206
2023 Q2	$1.28M	Hold	20,000	–	–	0.02%	200
2023 Q1	$1.39M	Buy	+20,000	New	+$1.41M	0.03%	179
2022 Q2	–	Sell	-35,000	Closed	-$2.56M	–	254
2022 Q1	$2.56M	Hold	35,000	–	–	0.04%	205
2021 Q4	$2.18M	Buy	+35,000	New	+$2.05M	0.04%	204
2018 Q2	–	Sell	-16,000	Closed	-$1.01M	–	287
2018 Q1	$1.01M	Buy	+16,000	New	+$1.03M	0.02%	191
2017 Q2	–	Sell	-127,680	Closed	-$6.94M	–	305
2017 Q1	$6.94M	Buy	+127,680	New	+$7M	0.13%	143
2016 Q4	–	Sell	-90,000	Closed	-$4.85M	–	309
2016 Q3	$4.85M	Buy	+90,000	New	+$5.78M	0.07%	208
2016 Q2	–	Sell	-95,000	Closed	-$6.07M	–	462
2016 Q1	$6.07M	Buy	+95,000	New	+$5.99M	0.09%	173

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Advent Capital Management's BMY Position: Q4 2025 in Review

Advent Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 75,000 shares — an estimated $3.38M sold.

Advent Capital Management first reported a position in BMY in Q1 2016 and held it in 9 quarters. The position peaked at $6.94M in Q1 2017. 2,451 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Advent Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Advent Capital Management sold 75,000 Bristol-Myers Squibb shares in Q4 2025, an estimated $3.38M.
Advent Capital Management first reported a position in Bristol-Myers Squibb in Q1 2016 and held it in 9 quarters.
Advent Capital Management's Bristol-Myers Squibb position peaked at $6.94M in Q1 2017.
2,451 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Advent Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.